 The FDA has granted Orphan Drug designation to TC Biopharm Ltds NASDAQ: TCBP lead product OmnImmune for use in Acute Myeloid Leukemia. After reviewing the Phase 1b2a trial results in relapsedrefractory AML patients, the FDA approved the Companys application. 